Sugi Predict

Sugi Predict / Compounds / SCHEMBL18546352

SCHEMBL18546352

SCHEMBL18546352

CC(C)(C)N(Cc1cnc(Nc2cc(COc3ccc(N)c4ccccc34)ccn2)cn1)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HCK P08631 12/20 0.37
▸ MAPK12 P53778 12/20 0.37
▸ MAPK14 Q16539 12/20 0.37
▸ SRC P12931 2/20 0.37
▸ MRGPRX4 Q96LA9 1/20 0.35
▸ LNPEP Q9UIQ6 1/20 0.34
▸ NR3C2 P08235 1/20 0.33
▸ AAK1 Q2M2I8 1/20 0.33
▸ GSK3A P49840 1/20 0.32
▸ TYK2 P29597 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18546443 0.87 ALDH1A1 (0.38) HCKMAPK12MAPK14SRC
SCHEMBL18546444 0.87 ALDH1A1 (0.38) HCKMAPK12MAPK14SRC
SCHEMBL17008508 0.84 HCK (0.36) HCKMAPK12MAPK14SRCMRGPRX4
SCHEMBL17008526 0.83 IKBKE (0.40) HCKMAPK12MAPK14SRCMRGPRX4
SCHEMBL31086673 0.83 IKBKE (0.40) HCKMAPK12MAPK14SRCMRGPRX4
SCHEMBL18567057 0.83 HDAC1 (0.39) HCKMAPK12MAPK14SRCAAK1
SCHEMBL28577141 0.83 HCK (0.35) HCKMAPK12MAPK14SRCMRGPRX4
SCHEMBL31086563 0.83 HCK (0.35) HCKMAPK12MAPK14SRCMRGPRX4
SCHEMBL17017129 0.82 MRGPRX4 (0.40) HCKMAPK12MAPK14SRCMRGPRX4
Hydrochloric Acid SCHEMBL17008549 0.81 MRGPRX4 (0.40) HCKMAPK12MAPK14SRCMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11142515-B2 Pyrazolyl-ureas as kinase inhibitors RESPIVERT LIMITED (GB) 2021-10-12 — — US disclosed
EP-3418279-B1 DRY POWDER PHARMACEUTICAL FORMULATION RESPIVERT LTD (GB) 2021-01-20 — — EP disclosed
US-10294216-B2 Pyrazolyl ureas as kinase inhibitors RESPIVERT LIMITED (GB) 2019-05-21 — — US disclosed
EP-3418279-A1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS Respivert Limited (GB) 2018-12-26 — — EP disclosed
EP-3105223-B1 PYRAZOLYL-UREAS AS KINASE INHIBITORS RESPIVERT LTD (GB) 2018-09-12 — — EP disclosed
US-20180118719-A1 PYRAZOLYL UREAS AS KINASE INHIBITORS RESPIVERT LIMITED (GB) 2018-05-03 — — US disclosed
US-9884845-B2 Pyrazolyl-ureas as kinase inhibitors RESPIVERT LIMITED (GB) 2018-02-06 — — US disclosed
US-20170057945-A1 NOVEL COMPOUNDS RESPIVERT LIMITED (GB) 2017-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294216-B2 Pyrazolyl ureas as kinase inhibitors MAP3K1, MAP3K2, MAP3K8 HCK 773/4885MAPK12 43/4885MAPK14 18/4885
US-20180118719-A1 PYRAZOLYL UREAS AS KINASE INHIBITORS MAP3K1, MAPK1, MAP3K7 HCK 553/4885MAPK12 37/4885MAPK14 16/4885
US-11142515-B2 Pyrazolyl-ureas as kinase inhibitors MAPK1, MAP3K1, MAP3K8 HCK 730/4885MAPK12 37/4885MAPK14 12/4885
US-20170057945-A1 NOVEL COMPOUNDS MAPK1, MAPK6, MAPKAPK2 HCK 2965/4885MAPK12 13/4885MAPK14 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.